Summaries & Associations of Study Results
TR-350 Tribromomethane
Target Organs and Levels of Evidence
NTP Technical Report Number 350
Produced from Chemtrack Database 09/19/01
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| TRIBROMOMETHANE 75-25-2 |
04/18/88 | SYNTHESIS OF PHARMACEUTICALS, IN SHIPBUILDING, AIRCRAFT INDUSTRY, IN FIRE-RESISTANT CHEMICALS, SEDATIVE MEDICATION, ANTITUSSIVE, ANTISEPTIC (HSDB 1990) | Gavage R&FM: 0,100,200, MM: 0,50,100 MG/KG/50 PER GROUP | T.S.I. Mason Laboratories, Inc. |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: SOME EVIDENCE | INTESTINES: ADENOMATOUS POLYP 0/50 0/50 2/50 OR ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50 | |||
| NON-NEOPLASTIC LESIONS: | LIVER: FATTY CHANGE 23/50 49/50 50/50; INFLAMMATION, CHRONIC ACTIVE 0/50 29/50 23/50; NECROSIS 7/50 3/50 20/50 | |||
| FR: CLEAR EVIDENCE | INTESTINES: ADENOMATOUS POLYP 0/48 1/50 6/49 OR ADENOCARCINOMA 0/48 0/50 2/49 COMBINED 0/48 1/50 8/49 | |||
| NON-NEOPLASTIC LESIONS: | LIVER: FATTY CHANGE 19/50 39/49 46/50; INFLAMMATION, CHRONIC ACTIVE 9/50 8/49 27/50; MIXED CELL FOCUS 8/50 25/49 28/50 | |||
| MM: NO EVIDENCE | ||||
| FM: NO EVIDENCE | ||||
Web page last updated on February 10, 2006
